NO20035317L - Antineoplastiske kombinasjoner - Google Patents

Antineoplastiske kombinasjoner

Info

Publication number
NO20035317L
NO20035317L NO20035317A NO20035317A NO20035317L NO 20035317 L NO20035317 L NO 20035317L NO 20035317 A NO20035317 A NO 20035317A NO 20035317 A NO20035317 A NO 20035317A NO 20035317 L NO20035317 L NO 20035317L
Authority
NO
Norway
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
NO20035317A
Other languages
English (en)
Norwegian (no)
Other versions
NO20035317D0 (no
Inventor
Gary Dukart
Jr James Joseph Gibbons
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20035317D0 publication Critical patent/NO20035317D0/no
Publication of NO20035317L publication Critical patent/NO20035317L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20035317A 2001-06-01 2003-11-28 Antineoplastiske kombinasjoner NO20035317L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
NO20035317D0 NO20035317D0 (no) 2003-11-28
NO20035317L true NO20035317L (no) 2003-12-22

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035317A NO20035317L (no) 2001-06-01 2003-11-28 Antineoplastiske kombinasjoner

Country Status (17)

Country Link
EP (1) EP1392286A2 (https=)
JP (1) JP2004532883A (https=)
KR (1) KR100875611B1 (https=)
CN (1) CN100496485C (https=)
AU (2) AU2002259309B2 (https=)
BR (1) BR0210101A (https=)
CA (1) CA2447732A1 (https=)
CO (1) CO5540294A2 (https=)
EA (1) EA007530B1 (https=)
HU (1) HUP0400006A2 (https=)
IL (1) IL158800A0 (https=)
MX (1) MXPA03010907A (https=)
NO (1) NO20035317L (https=)
NZ (1) NZ529877A (https=)
PL (1) PL367267A1 (https=)
SG (1) SG153647A1 (https=)
WO (1) WO2002098416A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL409579A1 (pl) 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) * 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
RU2487711C2 (ru) * 2005-11-21 2013-07-20 Новартис Аг Лечение нейроэндокринных опухолей
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
ATE135583T1 (de) * 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL409579A1 (pl) * 2001-02-19 2015-03-02 Novartis Ag Leczenie raka

Also Published As

Publication number Publication date
IL158800A0 (en) 2004-05-12
HUP0400006A2 (hu) 2004-04-28
EA200301319A1 (ru) 2004-04-29
SG153647A1 (en) 2009-07-29
AU2002259309B2 (en) 2008-05-01
NO20035317D0 (no) 2003-11-28
CO5540294A2 (es) 2005-07-29
CN1646120A (zh) 2005-07-27
EA007530B1 (ru) 2006-10-27
KR100875611B1 (ko) 2008-12-24
AU2008202690A1 (en) 2008-07-10
KR20040025923A (ko) 2004-03-26
NZ529877A (en) 2006-08-31
MXPA03010907A (es) 2004-02-17
BR0210101A (pt) 2004-06-08
CA2447732A1 (en) 2002-12-12
JP2004532883A (ja) 2004-10-28
WO2002098416A2 (en) 2002-12-12
WO2002098416A3 (en) 2003-03-13
EP1392286A2 (en) 2004-03-03
PL367267A1 (en) 2005-02-21
CN100496485C (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
DK1414438T3 (da) Antineoplastiske kombinationer
IS7291A (is) Merkt kirni
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50214313D1 (de) Koaxialmagentventil
DE50208022D1 (de) Wischblatt
DE60117032D1 (de) Glasfaserspleissverstärkung
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50212173D1 (de) sgängern
DE50204386D1 (de) Kreuztransducer
DE50204551D1 (de) Kugelgelenk
ATE335486T1 (de) Hydrazono-malonitrile
DE50211604D1 (de) Chlag
DE50209410D1 (de) Kugelgelenk
NO20035317L (no) Antineoplastiske kombinasjoner
DE60112475D1 (de) Einschraubenverdichter
DE50204794D1 (de) Kugelgelenk
DE50214628D1 (de) Ckaufbaudynamik
DE50203412D1 (de) Schwenkkolbenverdränger
DE50203984D1 (de) Kugelgelenk
DE60130379D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DE50201862D1 (de) Messwandler
DE60129205D1 (de) Mittelspannungskabelendverschluss
DE50214703D1 (de) Rpern
DE50203093D1 (de) Losradlager

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application